Table 1.
Baseline characteristics of analysis population
| Ad5-nCoV-IH | BNT-IM | Total | ||
|---|---|---|---|---|
| Gender | ||||
| Male | n(%) | 167(61.85) | 160(59.48) | 327(60.67) |
| Female | n(%) | 103(38.15) | 109(40.52) | 212(39.33) |
| Total | n(miss) | 270(0) | 269(0) | 539(0) |
| Age | ||||
| Mean(SD) | 34.5(10.73) | 34.4(10.60) | 34.5(10.66) | |
|
Median Q1,Q3 |
32.0 26.0,41.0 |
32.0 26.0,41.0 |
32.0 26.0,41.0 |
|
| Race | ||||
| Malay | n(%) | 205(75.93) | 208(77.32) | 413(76.62) |
| Chinese | n(%) | 42(15.56) | 43(15.99) | 85(15.77) |
| Indian | n(%) | 7(2.59) | 6(2.23) | 13(2.41) |
| Other | n(%) | 16(5.93) | 12(4.46) | 28(5.19) |
| Total | n(miss) | 270(0) | 269(0) | 539(0) |
| History of RT-PCR/RTK-confirmed SARS-CoV-2 infections | ||||
| Yes | n(%) | 145(53.70) | 139(51.67) | 284(52.69) |
| No | n(%) | 125(46.30) | 130(48.33) | 255(47.31) |
| Total | n(miss) | 270(0) | 269(0) | 539(0) |
| Vaccination history grouping | ||||
| AZ + AZ + X | n(%) | 69(25.56) | 50(18.59) | 119(22.08) |
| mRNA+mRNA+X | n(%) | 106(39.26) | 113(42.01) | 219(40.63) |
| ICV + ICV + X | n(%) | 88(32.58) | 98(36.43) | 186(34.52) |
| Others | n(%) | 7(2.59) | 8(2.97) | 15(2.78) |
| Total | n(miss) | 270(0) | 269(0) | 539(0) |
| Interval between second injection in the primary series immunization and the first booster, days | ||||
| n(miss) | 270(0) | 269(0) | 539(0) | |
| Mean(SD) | 167.7(40.39) | 171.9(37.97) | 169.8(39.22) | |
| Median | 166.0 | 169.0 | 168.0 | |
| Q1,Q3 | 139.0,190.0 | 142.0,199.0 | 140.0,196.0 | |
| Min,Max | 58,330 | 83,280 | 58,330 | |
| Interval between first booster and second booster, days | ||||
| n(miss) | 270(0) | 269(0) | 539(0) | |
| Mean(SD) | 279.1(39.81) | 282.1(43.42) | 280.6(41.63) | |
| Median | 274.0 | 275.0 | 274.0 | |
| Q1,Q3 | 256.0,305.0 | 256.0,313.0 | 256.0,312.0 | |
| Min,Max | 116,363 | 149,449 | 116,449 | |
| Pre-existing immunity, GMC of anti-spike RBD IgG antibodies (Wild-type) PPS | ||||
| n(miss) | 270(0) | 268(0) | 539(0) | |
| Mean(SD) | 1273.45 (3.11) | 1231.70 (3.41) | 1252.48 (3.25) | |
| Median | 1335.59 | 1283.77 | 1306.73 | |
| Q1,Q3 | 572.00,2975.97 | 510.775,2930.177 | 563.25,2973.38 | |
| Min,Max | 27.79,16431.60 | 2.67,68418.90 | 2.67,68418.90 | |
| 95%CI | 1111.45,1459.07 | 1062.93,1427.27 | 1133.35,1384.13 | |
| Pre-existing immunity, GMT of neutralizing antibodies against Omicron Pseudovirus variants (BA.4/5) (PPS) | ||||
| n(miss) | 270(0) | 268(0) | 538(0) | |
| Mean(SD) | 286.92(3.76) | 319.38(3.95) | 302.65(3.85) | |
| Median | 301.45 | 322.49 | 313.00 | |
| Q1,Q3 | 124.00,700.00 | 145.00,854.98 | 132.00,751.00 | |
| Min,Max | 15.0,30882.0 | 15.0,45953.0 | 15.0,45953.0 | |
| 95%CI | 244.82, 336.26 | 270.75,376.75 | 269.98,339.28 | |
n actual number of participants observed and the corresponding percentage, RT-PCR/RTK real-time reverse transcription-polymerase chain reaction/rapid test kit, AZ = COVID-19 Vaccine ChAdOx1-S Recombinant, X first booster dose of any vaccine, mRNA tozinameran vaccine, ICV COVID-19 Vaccine (Vero Cell) Inactivated, GMC geometric mean concentration, Anti-spike RBD IgG anti-spike receptor-binding domain immunoglobulin G, PPS per-protocol set, GMT geometric mean titre, Ad5-nCoV-IH Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, BNT-IM intramuscular tozinameran vaccine.